Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zielinski

Showing results (11-20 of 546) with videos related to

Pageof 55
Sort By:
Clinical Breast Cancer|June 12, 2002
Gemcitabine/anthracycline combinations in metastatic breast cancerChristoph C Zielinski
ESMO Open|June 25, 2019
How I treat cancer special issueChristoph C Zielinski
Acta Medica Austriaca|March 1, 2005
[Impact of oncologic therapeutic concepts 2004]Christoph C Zielinski
ESMO Open|November 16, 2016
<i>ESMO Open-Cancer Horizons</i> and the future of oncologyChristoph C Zielinski
Acta Medica Austriaca|January 1, 1987
[Natural cellular immunity as the effector mechanism in tumor defense]C Zielinski, C Müller
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2009
Trastuzumab treatment in patients with breast cancer and metastatic CNS diseaseT Pieńkowski, C C Zielinski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
More postchemotherapy rheumatismI Michl, C C Zielinski
The Lancet. Oncology|September 29, 2022
Ukraine's neighbouring countries accept the burden of cancer care for refugeesChristiane Thallinger, Christoph C Zielinski
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2012
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agentsF André, C C Zielinski
Hepatology (Baltimore, Md.)|November 1, 1990
Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitisC Müller, C C Zielinski
Pageof 55

Showing results (11-20 of 546) with videos related to

Sort By:
Pageof 55
Clinical Breast Cancer|June 12, 2002
Gemcitabine/anthracycline combinations in metastatic breast cancerChristoph C Zielinski
ESMO Open|June 25, 2019
How I treat cancer special issueChristoph C Zielinski
Acta Medica Austriaca|March 1, 2005
[Impact of oncologic therapeutic concepts 2004]Christoph C Zielinski
ESMO Open|November 16, 2016
<i>ESMO Open-Cancer Horizons</i> and the future of oncologyChristoph C Zielinski
Acta Medica Austriaca|January 1, 1987
[Natural cellular immunity as the effector mechanism in tumor defense]C Zielinski, C Müller
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2009
Trastuzumab treatment in patients with breast cancer and metastatic CNS diseaseT Pieńkowski, C C Zielinski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
More postchemotherapy rheumatismI Michl, C C Zielinski
The Lancet. Oncology|September 29, 2022
Ukraine's neighbouring countries accept the burden of cancer care for refugeesChristiane Thallinger, Christoph C Zielinski
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2012
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agentsF André, C C Zielinski
Hepatology (Baltimore, Md.)|November 1, 1990
Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitisC Müller, C C Zielinski
Pageof 55